Form 4: Alnylam Pharmaceuticals CEO Yvonne Greenstreet Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Alnylam Pharmaceuticals CEO Yvonne Greenstreet exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 1, 2024, Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, exercised a stock option to acquire 15,148 shares of common stock at a price of $85 per share.
- Simultaneously, Greenstreet sold 15,148 shares of Alnylam common stock at $270 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 12, 2024.
- Following these transactions, Greenstreet directly owns 73,441 shares of Alnylam common stock.
- Greenstreet also indirectly owns 407 shares through a managed account and holds options for 17,352 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests that the transactions were pre-planned and not based on any material non-public information. These filings are common for executives of publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 02/28/2023 | Stock option fully vested |
| 03/12/2024 | Rule 10b5-1(c) trading plan adopted |
| 08/01/2024 | Exercise of stock options and sale of shares |
| 08/02/2024 | Date of signature |
| 02/27/2029 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.